During the last session, AN2 Therapeutics Inc (NASDAQ:ANTX)’s traded shares were 1.02 million, with the beta value of the company hitting -0.18. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday loss of -3.42% or -$0.04. The 52-week high for the ANTX share is $22.22, that puts it down -1866.37 from that peak though still a striking 23.01% gain since the share price plummeted to a 52-week low of $0.87. The company’s market capitalization is $33.72M, and the average intraday trading volume over the past 10 days was 1.36 million shares, and the average trade volume was 565.17K shares over the past three months.
AN2 Therapeutics Inc (ANTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. ANTX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.37.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AN2 Therapeutics Inc (NASDAQ:ANTX) trade information
AN2 Therapeutics Inc (ANTX) registered a -3.42% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.42% in intraday trading to $1.13, hitting a weekly high. The stock’s 5-day price performance is 2.73%, and it has moved by -55.86% in 30 days. Based on these gigs, the overall price performance for the year is -92.51%. The short interest in AN2 Therapeutics Inc (NASDAQ:ANTX) is 0.39 million shares and it means that shorts have 0.42 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 79.45% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $22 respectively. As a result, ANTX is trading at a discount of -1846.9% off the target high and -76.99% off the low.
AN2 Therapeutics Inc (ANTX) estimates and forecasts
Statistics show that AN2 Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. AN2 Therapeutics Inc (ANTX) shares have gone down -62.58% during the last six months, with a year-to-date growth rate more than the industry average at 29.20% against 18.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 43.10% this quarter and then jump 49.10% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -73.03%. While earnings are projected to return 28.01% in 2024.
ANTX Dividends
AN2 Therapeutics Inc is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
AN2 Therapeutics Inc (NASDAQ:ANTX)’s Major holders
AN2 Therapeutics Inc insiders own 25.36% of total outstanding shares while institutional holders control 72.82%, with the float percentage being 97.56%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 59.0 institutions own stock in it. As of 2024-06-30, the company held over 5.55 million shares (or 18.6515% of all shares), a total value of $11.94 million in shares.
The next largest institutional holding, with 3.22 million shares, is of OCTAGON CAPITAL ADVISORS LP’s that is approximately 10.8196% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.92 million.
